NxStage Medical Inc. (NXTM) PT Set at $25.00 by Northland Securities
Northland Securities set a $25.00 price target on NxStage Medical Inc. (NASDAQ:NXTM) in a report released on Thursday morning. The firm currently has a a buy rating on the medical device company’s stock.
A number of other equities analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of NxStage Medical from a buy rating to a hold rating in a research note on Wednesday, August 10th. BTIG Research reissued a buy rating and set a $29.00 target price on shares of NxStage Medical in a research note on Sunday, August 7th. Jefferies Group lifted their target price on shares of NxStage Medical from $24.00 to $27.00 and gave the stock a buy rating in a research note on Friday, August 5th. Canaccord Genuity lifted their target price on shares of NxStage Medical from $22.00 to $26.00 and gave the stock a buy rating in a research note on Tuesday, August 2nd. Finally, Piper Jaffray Cos. reissued a buy rating and set a $21.00 target price on shares of NxStage Medical in a research note on Friday, June 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. NxStage Medical presently has an average rating of Buy and a consensus target price of $26.43.
NxStage Medical (NASDAQ:NXTM) opened at 24.21 on Thursday. NxStage Medical has a 1-year low of $13.49 and a 1-year high of $26.07. The firm’s market capitalization is $1.56 billion. The stock’s 50 day moving average is $23.69 and its 200-day moving average is $19.60.
NxStage Medical (NASDAQ:NXTM) last announced its earnings results on Thursday, August 4th. The medical device company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. NxStage Medical had a negative net margin of 2.06% and a negative return on equity of 3.79%. The business earned $92.20 million during the quarter, compared to the consensus estimate of $89.44 million. During the same quarter last year, the firm earned ($0.08) earnings per share. NxStage Medical’s quarterly revenue was up 14.8% on a year-over-year basis. Analysts forecast that NxStage Medical will post ($0.12) EPS for the current year.
In related news, Director Craig W. Moore sold 3,000 shares of the business’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $23.31, for a total transaction of $69,930.00. Following the transaction, the director now directly owns 90,739 shares in the company, valued at $2,115,126.09. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.70% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC boosted its position in NxStage Medical by 1,459.3% in the second quarter. Acrospire Investment Management LLC now owns 4,678 shares of the medical device company’s stock valued at $101,000 after buying an additional 4,378 shares during the period. Pacad Investment Ltd. purchased a new position in NxStage Medical during the second quarter valued at $111,000. BNP Paribas Arbitrage SA boosted its position in NxStage Medical by 57.5% in the second quarter. BNP Paribas Arbitrage SA now owns 5,548 shares of the medical device company’s stock valued at $120,000 after buying an additional 2,026 shares during the period. BlackRock Inc. boosted its position in NxStage Medical by 50.6% in the second quarter. BlackRock Inc. now owns 6,299 shares of the medical device company’s stock worth $136,000 after buying an additional 2,116 shares during the last quarter. Finally, Cutler Group LP boosted its position in NxStage Medical by 28.3% in the second quarter. Cutler Group LP now owns 7,168 shares of the medical device company’s stock worth $155,000 after buying an additional 1,583 shares during the last quarter. Institutional investors and hedge funds own 98.26% of the company’s stock.
About NxStage Medical
NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.